📰 ReutersReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 21:00:41时区推断·⟳ 抓取 21:00:56·⚡ 决策 07-28 21:36:14 +35m18s·91.1 天前
Incyte上调2026年收入指引但该催化已在近72小时内处理
Incyte将2026年收入指引从47.7亿-49.4亿美元上调至51.3亿-52.6亿美元，主要来自Opzelura CMS和解带来的3.00亿-3.10亿美元全年净销售增量。
📄 原文Reuters↗ 原文
Drugmaker Incyte Corp (INCY.O) reported on Tuesday higher second-quarter earnings and raised its annual revenue forecas…
不做 Incyte（INCY.US）
同一具体催化已在近72小时处理过：Incyte二季度业绩上修销售指引但主要增量含已预告CMS一次性收益且费用同步大幅上调；本条不重复推卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 high · price-in 风险 high ↗
关键理由
- Incyte将2026年收入指引从47.7亿-49.4亿美元上调至51.3亿-52.6亿美元，主要来自Opzelura CMS和解带来的3.00亿-3.10亿美元全年净销售增量。
- 二季度调整后EPS为3.09美元，高于LSEG预期2.10美元；二季度净销售同比增长40%至14.9亿美元，含2.46亿美元CMS和解相关一次性非现金收益。
- 查重命中近72小时已处理同一具体催化，避免重复推卡。
主要风险
- INCB160058血癌项目停止进一步开发，虽分析师称不意外，但削弱部分管线期权。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-28 · 影响 weakens
内部研报提示本次收入超预期主要由CMS和解非现金收益驱动，且该催化已被处理过。
检索:Incyte Opzelura CMS settlement 2026 revenue forecast 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,713 字
Drugmaker Incyte Corp (INCY.O) reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled a lawsuit with the U.S. government over Medicaid rebates tied to eczema cream Opzelura.
Here are the details:
The U.S. drugmaker raised its 2026 revenue forecast to between $5.13 billion and $5.26 billion, from its previous forecast of $4.77 billion to $4.94 billion.
Incyte reached a settlement in June with the Centers for Medicare & Medicaid Services over rebate criteria for Opzelura, its eczema and vitiligo treatment.
The agreement will add an estimated $300 million to $310 million to Opzelura's net sales for the full-year 2026.
CMS agreed not to classify Opzelura as a line extension of Incyte's older drug Jakafi, while the company agreed to withdraw its lawsuit challenging the regulations.
When a branded drug is reformulated, the new drug is classified by the Medicare agency as a line extension.
Total net sales for the second quarter increased 40% to $1.49 billion, driven by a one-time, non-cash benefit of $246 million related to the CMS litigation settlement.
Incyte also said it has discontinued further development of the INCB160058 drug for blood cancer and will prioritize its next-generation therapies.
"Although disappointing, we are not surprised by the update given the INCB160058 program has been delayed and faced formulation challenges," said William Blair analyst Matt Phipps.
Second-quarter Jakafi sales rose to $816.7 million, while Opzelura net sales came at $449.7 million.
Incyte earned quarterly adjusted profit of $3.09 per share, surpassing estimates of $2.10 per share, according to data compiled by LSEG.
Here are the details:
The U.S. drugmaker raised its 2026 revenue forecast to between $5.13 billion and $5.26 billion, from its previous forecast of $4.77 billion to $4.94 billion.
Incyte reached a settlement in June with the Centers for Medicare & Medicaid Services over rebate criteria for Opzelura, its eczema and vitiligo treatment.
The agreement will add an estimated $300 million to $310 million to Opzelura's net sales for the full-year 2026.
CMS agreed not to classify Opzelura as a line extension of Incyte's older drug Jakafi, while the company agreed to withdraw its lawsuit challenging the regulations.
When a branded drug is reformulated, the new drug is classified by the Medicare agency as a line extension.
Total net sales for the second quarter increased 40% to $1.49 billion, driven by a one-time, non-cash benefit of $246 million related to the CMS litigation settlement.
Incyte also said it has discontinued further development of the INCB160058 drug for blood cancer and will prioritize its next-generation therapies.
"Although disappointing, we are not surprised by the update given the INCB160058 program has been delayed and faced formulation challenges," said William Blair analyst Matt Phipps.
Second-quarter Jakafi sales rose to $816.7 million, while Opzelura net sales came at $449.7 million.
Incyte earned quarterly adjusted profit of $3.09 per share, surpassing estimates of $2.10 per share, according to data compiled by LSEG.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。